Welcome to our dedicated page for Icosavax news (Ticker: ICVX), a resource for investors and traders seeking the latest updates and insights on Icosavax stock.
Icosavax, Inc. (NASDAQ: ICVX) is a Seattle-based biopharmaceutical company committed to developing safe and effective vaccines targeting infectious diseases with significant unmet medical needs. Founded in 2017, the company harnesses breakthrough computationally-designed virus-like particle (VLP) technology, exclusively licensed from the Institute for Protein Design at the University of Washington.
Icosavax’s lead vaccine candidate, IVX-A12, is currently in Phase 2 clinical trials and targets respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), aiming to deliver a first-in-class bivalent combination vaccine for older adults. Recent trial data indicates promising immune responses post-revaccination with their component IVX-121, suggesting potential for durable protection and differentiation in the RSV vaccine market.
The company's VLP platform is designed to enable the multivalent, particle-based display of complex viral antigens, aiming to induce broad, robust, and durable immune responses. This innovative technology is also being leveraged to develop vaccines targeting other critical pathogens, including influenza and SARS-CoV-2.
Icosavax is actively engaged in various stages of clinical trials and expects to announce topline interim data for the IVX-A12 Phase 2 trial by the end of 2023. The company continues to advance its pipeline with a vision of creating combination and pan-respiratory vaccines to address life-threatening respiratory diseases while aiming to reduce healthcare costs.
In addition to its promising vaccine candidates, Icosavax has established important partnerships and relies on third-party collaborations for manufacturing, research, and clinical testing. The company is navigating regulatory landscapes in the U.S. and internationally to bring its innovative solutions to market.
For further information, visit the Icosavax website.
The FDA has granted Fast Track Designation for Icosavax's IVX-A12, a bivalent VLP vaccine targeting RSV and hMPV. The company completed dosing in the Phase 1 trial, with topline interim results expected in Q2 2023 and a Phase 2 trial initiation planned for H2 2023. As of December 31, 2022, Icosavax reported cash and investments totaling $219.4 million, down from $280.7 million in 2021. In 2022, R&D expenses rose to $65.4 million, up from $38.8 million in 2021, primarily due to increased clinical activities. The net loss for the year was $91.8 million, with a diluted loss per share of $2.31, reflecting rising expenses.
Icosavax, a biopharmaceutical company specializing in vaccine development, will participate in two upcoming investor conferences. The Cowen 43rd Annual Health Care Conference features CEO Adam Simpson on March 7 at 9:10 am ET in Boston. Additionally, Icosavax will present virtually at the Oppenheimer 33rd Annual Healthcare Conference on March 13 at 12:40 pm ET. Investors can access audio webcasts of both events via the company's website, with replays available for 90 days post-event. Icosavax focuses on using its virus-like particle platform to create vaccines for respiratory diseases, including RSV, hMPV, and SARS-CoV-2.
Icosavax, Inc. (Nasdaq: ICVX) announced that the FDA granted Fast Track designation for its IVX-A12 vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults over 60. This designation aims to expedite the development of drugs addressing serious conditions. The vaccine could help mitigate the estimated 177,000 hospitalizations and 14,000 deaths caused by RSV annually in the U.S. Icosavax anticipates topline results from its Phase 1 study in mid-2023, with a Phase 2 trial planned for the second half of 2023.
Icosavax recently reported promising six-month immunogenicity data for its vaccine candidate IVX-121 against RSV, demonstrating sustained immune response. The Phase 1 trial for IVX-A12, a bivalent vaccine for RSV and hMPV, is progressing with topline results expected mid-2023, followed by a Phase 2 initiation in the second half of the year. The company also appointed Jennifer Raymond as Senior Vice President of Technical Operations. With a strong cash position of $222.5 million, Icosavax is well-positioned to fund operations through at least 2024.
Icosavax, focused on vaccines for respiratory diseases, announced promising six-month results from its Phase 1/1b study of IVX-121 against RSV. The data shows sustained neutralizing antibody responses at 64-98% of the levels recorded at day 28, demonstrating the vaccine's durability. IVX-121 remains well tolerated, with no safety concerns reported. Additionally, the company is advancing IVX-A12, a bivalent candidate targeting RSV and hMPV. Icosavax plans to share a 12-month immunogenicity update in mid-2023.
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company focused on developing vaccines for respiratory diseases, announced its participation in the 5th Annual Evercore ISI HealthCONx Conference from November 29 to December 1, 2022. CEO Adam Simpson will engage in a fireside chat on December 1 at 3:55 pm ET. Attendees can access a live audio webcast from the company's Investor Relations webpage, with a replay available for 90 days post-event. Icosavax aims to create multivalent vaccines using its innovative virus-like particle (VLP) technology.
FAQ
What is the market cap of Icosavax (ICVX)?
What does Icosavax, Inc. specialize in?
Where is Icosavax, Inc. located?
What is the focus of Icosavax's lead vaccine candidate IVX-A12?
What technology does Icosavax use for its vaccines?
What recent achievement has Icosavax made in its clinical trials?
When is Icosavax expected to announce the topline interim data for IVX-A12?
What other diseases is Icosavax targeting with its vaccine pipeline?
What is the underlying goal of Icosavax’s vaccine development?
Who are the key contacts for media and investor relations at Icosavax?
Where can I find more information about Icosavax?
